EUCTR2009-011617-25-BE进行中（未招募）1 期
A Phase III Clinical Trial to Study the Immunogenicity, Tolerability, and Manufacturing Consistency of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered in Preadolescents and Adolescents (9 to 15 year olds), with a Comparison to Young Women (16 to 26 year olds). - Immunogenicity, Tolerability, and Manufacturing Consistency study of a Multivalent HPV, VLP vaccine
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,0 个研究点目标入组 2,000 人开始时间: 2009年7月14日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 2,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subject was enrolled in Protocol 002 between 9 and 15 years of age and received 3 doses of 9-valent HPV L1 VLP vaccine.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 4
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •Subjects who are concurrently enrolled in clinical studies that would involve or interfere with the collection of genital specimens.
研究者
相似试验
已完成
3 期
A Study of V503 (Multivalent HPV Vaccine) in Preadolescents and Adolescents. This study will evaluate the immunogenicity and tolerability of V503 in preadolescent and adolescent subjects between 9 and 15 years old and demonstrate the consistency of the manufactured vaccine through assessment of 3 different final manufacturing process lots of V503.CTRI/2009/091/000767Merck Sharp and Dohme2,800
进行中（未招募）
3 期
This study will evaluate the immunogenicity and tolerability of V503 ipreadolescent and adolescent subjects between 9 and 15 years old andemonstrate the consistency of the manufactured vaccine throughassessment of 3 different final manufacturing process lots of V503.CTRI/2013/09/004012Merck Sharp and Dohme2,800
进行中（未招募）
1 期
A Phase III Clinical Trial to Study the Immunogenicity, Tolerability, and Manufacturing Consistency of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (9 to 15 year olds) with a Comparison to Young Women (16 to 26 year olds)Cervical CancersVulvar CancerVaginal CancerGenital LesionsPAP Test AbnormalitiesHPV InfectionsMedDRA version: 20.1Level: LLTClassification code 10063001Term: Human papilloma virus infectionSystem Organ Class: 100000004862EUCTR2009-011617-25-Outside-EU/EEAMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
已完成
不适用
A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)PER-081-09MERCK SHARP & DOHME PERU S.R.L.,
进行中（未招募）
1 期
Immunogenicity, Tolerability, and Manufacturing Consistency study of aMultivalent HPV, VLP vaccine.Prevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, Pap test abnormalities, and persistent infection caused by human papillomavirus (HPV) Types 6, 11, 16, 18, 31, 33, 45, 52, and 58.MedDRA version: 20.0Level: LLTClassification code 10063001Term: Human papilloma virus infectionSystem Organ Class: 100000004862EUCTR2009-011617-25-PLMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.3,123